INTRODUCTION AND OBJECTIVES: MRI-TRUS fusion prostate biopsy(FB), also referred to as "targeted biopsy", has been shown to improve detection of clinically significant prostate cancer and reduce the detection of indolent cancers. Given the improvements in MRI targeted biopsy many urologist and patients alike have questioned the need for extended systematic sextant biopsy(SB) when FB is possible. We sought to determine if SB is still necessary in the modern era of MRI targeted biopsy.
METHODS Figure 1) .
CONCLUSIONS: MRI targeted biopsy significantly increases the likelihood of detecting clinically significant cancer without a concomitant increase in detection of low grade disease. These finding strongly support the use of routine MRI targeted biopsy when possible. While systematic biopsy did lead to an increase in detection of indolent cancers, a sufficiently large proportion of aggressive cancers were detected on systematic biopsy only, suggested targeted biopsy alone does not perform well enough to forgo systematic biopsy at this time. 
MP13-03 NEED FOR SYSTEMIC 12-CORE BIOPSY CONCURRENT WITH MRI TARGETED BIOPSY OF PI-RADS 4 AND PI-RADS 5 LESIONS
INTRODUCTION AND OBJECTIVES: The risk of transrectal prostate biopsy associated infection increases with number of cores taken. Our objective was to assess the need for systemic 12-core biopsy concurrent with MRI targeted biopsy (TB) of PI-RADS 4 and 5 regions of interest in patients with previous negative biopsy and rising prostate specific antigen, or positive prostate biopsy in candidates for active surveillance.
METHODS: Retrospective analysis of a single institution. Prostate Lesions were graded on mpMRI by a single Fellowship trained radiology group. Pathology was reviewed by a fellowship trained GU pathologist, all patient underwent a MRI-TB and concurrent systemic 12-core biopsy by one urologist. An upgrade was defined as cancer detected in a patient with no previous prostate biopsy or increase in the GS from any previous biopsy.
RESULTS: A total of 112 patients underwent an MRI-TB. There were 65 patients that had an upgrade of their prostate cancer after the TB and concurrent systemic 12 core biopsy (58%). Upgrade occurred in
